ORY (ORY) News
Follow ORY (ORY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Oryzon Genomics SA BME:ORY
NEWS | Sep 28, 2026, 06:25 AM UTC
L
ORYZON to Participate in Upcoming Events in September and October
MADRID and CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its
EQUITY | Sep 10, 2026, 12:04 PM UTC
M
Oryzon receives U.S. patent allowance for drug combo application
Oryzon has received a U.S. patent allowance for its iadademstat and gilteritinib drug combo application.
EQUITY | Aug 31, 2026, 06:17 AM UTC